DE60040136D1 - Ein neues chimäres protein für die prävention und die behandlung einer hiv infektion - Google Patents

Ein neues chimäres protein für die prävention und die behandlung einer hiv infektion

Info

Publication number
DE60040136D1
DE60040136D1 DE60040136T DE60040136T DE60040136D1 DE 60040136 D1 DE60040136 D1 DE 60040136D1 DE 60040136 T DE60040136 T DE 60040136T DE 60040136 T DE60040136 T DE 60040136T DE 60040136 D1 DE60040136 D1 DE 60040136D1
Authority
DE
Germany
Prior art keywords
prevention
treatment
proteins
hiv infection
chimeric protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60040136T
Other languages
German (de)
English (en)
Inventor
Edward A Berger
Castillo Christie M Del
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government Of United States, Us
Original Assignee
National Institutes of Health NIH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Health NIH filed Critical National Institutes of Health NIH
Application granted granted Critical
Publication of DE60040136D1 publication Critical patent/DE60040136D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10RNA viruses
    • C07K16/112Retroviridae (F), e.g. leukemia viruses
    • C07K16/114Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60040136T 1999-03-16 2000-03-16 Ein neues chimäres protein für die prävention und die behandlung einer hiv infektion Expired - Lifetime DE60040136D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12468199P 1999-03-16 1999-03-16
PCT/US2000/006946 WO2000055207A1 (en) 1999-03-16 2000-03-16 A novel chimeric protein for prevention and treatment of hiv infection

Publications (1)

Publication Number Publication Date
DE60040136D1 true DE60040136D1 (de) 2008-10-16

Family

ID=22416252

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60040136T Expired - Lifetime DE60040136D1 (de) 1999-03-16 2000-03-16 Ein neues chimäres protein für die prävention und die behandlung einer hiv infektion

Country Status (8)

Country Link
EP (1) EP1161455B1 (https=)
JP (1) JP2002538814A (https=)
AT (1) ATE407146T1 (https=)
AU (1) AU765218B2 (https=)
CA (1) CA2361292C (https=)
DE (1) DE60040136D1 (https=)
ES (1) ES2313886T3 (https=)
WO (1) WO2000055207A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925966D0 (en) 1999-11-02 1999-12-29 Petrik Juraj Threapeutic vaccines against variable viruses and other targets
IL141023A0 (en) * 2001-01-22 2002-02-10 Gavish Galilee Bio Appl Ltd Recombinant polypeptides for effective hiv neutralization
DK1390535T3 (da) * 2001-04-26 2010-12-06 Amgen Mountain View Inc Kombinatoriske biblioteker af monomer-domæner
ATE481109T1 (de) 2001-10-16 2010-10-15 Us Gov Health & Human Serv Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co- rezeptorkomplexen selektiert werden
US7368114B2 (en) 2001-10-25 2008-05-06 The United States Of America As Represented By The Department Of Health And Human Services Fusion protein including of CD4
US7566451B2 (en) 2002-05-06 2009-07-28 The United States Of America As Represented By The Department Of Health And Human Services Human immunodeficiency virus-neutralizing human antibodies with improved breadth and potency
US7803913B2 (en) 2002-05-06 2010-09-28 The United States Of America As Represented By The Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
WO2004110359A2 (en) * 2003-05-16 2004-12-23 Acorda Therapeutics, Inc. Fusion proteins for the treatment of cns
ES2319838B1 (es) * 2006-09-29 2010-02-11 Consejo Superior Investig. Cientificas Uso de inhibidores de la actividad de la proteina filamina a, para la elaboracion de composiciones farmaceuticas, compuestos inhibidores de dicha actividad, composiciones farmaceuticas y sus aplicaciones terapeuticas y procedimiento identificacion de dichos compuestos inhibidores.
WO2010070394A1 (en) * 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
CN111909278B (zh) 2014-01-27 2024-04-09 分子模板公司 Mhc i类表位递送多肽
AU2016271124C1 (en) * 2015-05-30 2020-05-14 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
MX2022000896A (es) * 2019-07-24 2022-02-14 Regeneron Pharma Receptores de antigenos quimericos con especificidad por mage-a4 y usos de los mismos.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU735460B2 (en) * 1996-06-14 2001-07-12 Aaron Diamond Aids Research Center, The Uses of a chemokine receptor for inhibiting HIV-1 infection
US6432699B1 (en) * 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A

Also Published As

Publication number Publication date
CA2361292A1 (en) 2000-09-21
ES2313886T3 (es) 2009-03-16
EP1161455B1 (en) 2008-09-03
EP1161455A1 (en) 2001-12-12
ATE407146T1 (de) 2008-09-15
AU765218B2 (en) 2003-09-11
JP2002538814A (ja) 2002-11-19
CA2361292C (en) 2012-05-29
WO2000055207A1 (en) 2000-09-21
AU3889600A (en) 2000-10-04

Similar Documents

Publication Publication Date Title
ATE407146T1 (de) Ein neues chimäres protein für die prävention und die behandlung einer hiv infektion
PH12021550793A1 (en) Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
MEP32008A (en) Specific binding agents of human angiopoietin-2
WO2022204316A3 (en) Variant nucleic acid libraries for cd3
AR068566A1 (es) Proteinas fijadoras de antigeno de factor de crecimiento del tipo factor de crecimiento epidermico fijador de heparina
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
DK1062226T3 (da) Nukleinsyreligander med høj affinitet mod komplementsystemets C5-protein
ATE409181T1 (de) Proteomimetische verbindungen und verfahren
HRP20090527T1 (hr) Imunoglobulini za neutraliziranje nogo-a, namijenjeni liječenju neuroloških bolesti
BRPI0214137B8 (pt) anticorpo monoclonal humano ou porção de ligação a antígeno do mesmo que se liga especificamente ao cd40 humano e o ativa, linhagem celular de hibridoma isolado, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento e método de fabricação dos referidos anticorpos ou porção de ligação a antígeno do mesmo
WO2004018649A3 (en) Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein
DE60223340D1 (de) Serpin-arzneistoffe zur behandlung einer hiv-infektion und verfahren zu deren verwendung
WO2003034903A3 (en) Psma antibodies and protein multimers
DE602004023724D1 (de) Verfahren zur chemischen synthese chimärischer immunglobulinproteine
UA87093C2 (ru) ГУМАНИЗИРОВАННЫЙ ИММУНОГЛОБУЛИН, КОТОРЫЙ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С БЕТА-АМИЛОИДНЫМ ПЕПТИДОМ (Аβ)
ATE375999T1 (de) Zusammensetzungen und verfahren zur behandlung von diabetes
EP1064403A4 (en) ANTISENSE MODULATION BY PECAM-1
BR9815367A (pt) Sequências de aminoácidos para terapia e profilaxia de doenças através da toxina clostridium difficile
ES2098274T3 (es) Anticuerpos monoclonales.
DE69618614D1 (de) NUKLEINSÄUREMOLEKÜLE MIT DER FÄHIGKEIT ZUR UNTERSCHEIDUNG VON PrPc UND PrPSc-PRIONPROTEIN-ISOFORMEN UND VERFAHREN ZU DEREN HERSTELLUNG
CO5280147A1 (es) Anticuerpo humano monoclonal
DE602004030041D1 (de) Verfahren und zusammensetzungen zur identifikation von rna-bindenden proteinen
ATE353337T1 (de) Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
ATE290881T1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, US

8364 No opposition during term of opposition